MedTrace Logo

A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery

NCT05528172 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 331

Last updated 2024-05-24

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of K-321 in subjects after cataract surgery

Conditions

  • Corneal Edema After Cataract Surgery

Interventions

DRUG

Ripasudil

K-321 ophthalmic solution

DRUG

Placebo

Placebo ophthalmic solution

Sponsors & Collaborators

  • Kowa Research Institute, Inc.

    lead INDUSTRY

Principal Investigators

  • Shona Pendse, MD, MMSc · Kowa Pharma Development Co.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-04
Primary Completion
2023-06-22
Completion
2023-06-22
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05528172 on ClinicalTrials.gov